Table 4.

Risk factors for developing anthracycline-induced cardiotoxicity.

Patient-related risk factors	•Preexisting cardiovascular risks, for instance, arterial hypertension, diabetes, smoking, renal failure, baseline left ventricular dysfunction, valvular heart disease, coronary disease, etc.
	•Female gender
	•Age >65 years or <18 years
	•African-American ancestry
	•Genetic factors
Therapy-related risk factors	•Cumulative dose of anthracyclines
	•Infusion regimen (For adults, continuous infusion is usually more tolerant compared with bolus dosing)
	•Concomitant use of other anticancer treatments like radiotherapy or trastuzumab